Study | Na | Type of cancer | Mean/ median follow-upb (months) | Association with MNA and | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Mortality/ poor survival | Progression-free survival/ Time to progression | Treatment maintenance/ -duration | Complications | Functional status/ -decline | Quality of Life | ||||||
Treatment toxicity | Postoperative complications | ADL | IADL | ||||||||
Aaldriks 2011 | 202 | Various | 9 | + + | + | ||||||
Aaldriks 2013a | 143 | Colorectal | 15 | any CT: + + adjuvant CT: – – palliative: + + | + + | ||||||
Aaldriks 2013b | 55 | Breast | 16 | + + | – | ||||||
Aaldriks 2015 | 44 | Various | 46 | – | + + | ||||||
Aaldriks 2016 | 494 | Various | 17 | + + | + + | ||||||
Allaire 2017 | 144 | Bladder | 0.2 or 2 | – – – – | |||||||
Aparicio 2018 | 102 | Colorectal | 20.4 | – | – | ||||||
Baier 2016 | 195 | Various | 6 | – | |||||||
Boulahssass 2018 | 1050 | Various | 3.3 | + + | |||||||
Decoster 2016 | 193 | Colorectal | 2–3 | Grade 4 HT: – – Grade 4 NHT: – – | – | – | |||||
Decoster 2018 | 252 | Colorectal | n.r. | + + | – | ||||||
Decoster 2019 | 2972 | Various | 3 | + + | |||||||
Dubruille 2015 | 90 | Hematological | 12 | – | |||||||
Extermann 2012 | n.a.c | Various | 1 | HT: – – NHT: + + | |||||||
Frasca 2018 | 1264 | Various | 12 36 60 | + + + + – – | |||||||
Ghosn 2017 | 100 | Various | 47.3 | – | |||||||
Giannotti 2019 | 99 | Colorectal | 12 | – | |||||||
Giannousi 2012 | 122 | Lung | 70 | + + | |||||||
Gioulbasanis 2011a | 173 | Lung | 24 | + + | + + | ||||||
Gioulbasanis 2011b | 115 | Lung | 38.2 | + + | |||||||
Gioulbasanis 2012 | 114 | Lung | 24.3 | + + | + + | ||||||
Gioulbasanis 2015 | 594 | Various | 27 | + + | |||||||
Goineau 2018 | 100 | Prostate | 2 | – | |||||||
Gu 2015 | 300 | Renal cell | 30.8 | + + | – –e | ||||||
Honecker 2018 | 160 | Prostate | n.r. | – | – | ||||||
Hoppe 2013 | 299 | Various | n.r. | + | |||||||
Kaibori 2016 | 71 | Hepatocellular | n.r. | – | |||||||
Kenig 2015 | 75 | Various | 1 | – | |||||||
Kenis 2017 | 439 | Various | n.r. | + + | + + | – | |||||
Kenis 2018 | Cohort A: 763 | Various | Cohort A: 61.4 | + + | |||||||
Cohort B: 402 | Cohort B: 45.7 | + + | |||||||||
Kim 2014 | 98 | Various | 15.1 | + + | |||||||
Kristjansson 2010 | 182 | Colorectal | 20 | + + | –f | ||||||
Liuu 2020 | 1092 | Various | 15.3 | + | |||||||
Lycke 2019 | 944 | Various | 12 | + + | |||||||
Martucci 2016 | 136 | Various | 12 | + + | |||||||
Mazzuca 2019 | ProLYOtind: 22 | Colorectal | 3 | + | |||||||
Placebo: 25 | |||||||||||
Michaan 2020 | 120 | Gynaecologic | > 4 | + + | |||||||
Molga 2020 | 98 | Hematological | n.r. | – | – | ||||||
Naito 2016 | 93 | Non-Hodgkin Lymphoma | n.r. | – | |||||||
Osborne 2017 | 178 | Prostate | 3 | – | |||||||
Park 2015 | 70 | Lymphomas | 21.5 | + + | + + | ||||||
Quinten 2019 | Surgery: 741 | Various | 3 | + + | |||||||
Chemo: 683 | – | ||||||||||
Retornaz 2020 | 97 | Colorectal | 16.7 | – | – | ||||||
Samuelsson 2019 | 49 | Colorectal | ≤0.1 | – | |||||||
Scholtz 2018 | 517 | Various | 1 | + | |||||||
Schütte 2015 | 51 | Hepatocellular | 7.3 | + | |||||||
Shin 2012 | 64 | Various | 2.1 | – | |||||||
Shiroyama 2017 | 30 | Lung | n.r. | + | |||||||
Soubeyran 2012 | 348 | Various | 6 | + + | |||||||
Stauder 2020 | 147 | Hematological | 24 | + | |||||||
van Deudekom 2019 | 102 | Head & Neck | 12 | + + | |||||||
van der Vlies 2019 | 99 | Various | n.r. | – | – | ||||||
Vlachostergios 2013 | 103 | Lung | 38.2 | + + | – | ||||||
Proportion of studies with significant results in multivariable analyses | 22/27 (=81%) | 3/5 (=40%) | 5/8 (=63%) | 1/5 (=20%) | 0/2 (=0%) | 1/3 (=33%) | 0/2 (=0%) | 2/2 (=100%) |